Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
47.3M
-
Shares change
-
-6.22M
-
Total reported value, excl. options
-
$399M
-
Value change
-
-$50.1M
-
Put/Call ratio
-
0.14
-
Number of buys
-
69
-
Number of sells
-
-66
-
Price
-
$8.43
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2022
170 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q3 2022.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.3M shares
of 62.2M outstanding shares and own 76.17% of the company stock.
Largest 10 shareholders include STATE STREET CORP (4.68M shares), RTW INVESTMENTS, LP (4.18M shares), FARALLON CAPITAL MANAGEMENT LLC (3.65M shares), BlackRock Inc. (3.46M shares), VANGUARD GROUP INC (2.94M shares), FMR LLC (2.81M shares), Point72 Asset Management, L.P. (2.54M shares), JOHNSON & JOHNSON (2.45M shares), Bain Capital Life Sciences Investors, LLC (2.26M shares), and MORGAN STANLEY (2.23M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.